| Literature DB >> 36044175 |
Wei-Wen Kuo1,2, Chih-Yang Huang3,4,5,6,7, Jing-Ying Lin8, Bruce Chi-Kang Tsai9, Hui-Chuan Kao10, Chien-Yi Chiang9, Yun-An Chen1, William Shao-Tsu Chen11,12, Tsung-Jung Ho13,14,15, Chun-Hsu Yao16,17,18,19.
Abstract
Diabetes-related brain complications have been reported in clinical patients and experimental models. The objective of the present study was to investigate the neuroprotective mechanisms of Lactobacillus reuteri GMNL-263 in streptozotocin (STZ)-induced diabetic rats. In this study, three different groups, namely control group, STZ-induced (55 mg/kg streptozotocin intraperitoneally) diabetic rats (DM), and DM rats treated with Lactobacillus reuteri GMNL-263 (1 × 109 CFU/rat/day), were utilized to study the protective effect of GMNL-263 in the hippocampus of STZ-induced diabetic rats. The results demonstrated that GMNL-263 attenuated diabetes-induced hippocampal damage by enhancing the cell survival pathways and repressing both inflammatory and apoptotic pathways. Histopathological analysis revealed that GMNL-263 prevented structural changes in the hippocampus in the DM group and decreased the level of inflammation and apoptosis in the hippocampus of DM rats. The IGF1R cell survival signaling pathway also improved after GMNL-263 treatment. These results indicate that probiotic GMNL-263 exerts beneficial effects in the brain of diabetic rats and has potential ability for clinical application.Entities:
Keywords: Diabetic mellitus; Hyperglycemia; Lactic acid bacteria; Lactobacillus reuteri; Streptozotocin
Year: 2022 PMID： 36044175 DOI： 10.1007/s12602-022-09982-w
Source DB: PubMed Journal: Probiotics Antimicrob Proteins ISSN： 1867-1306 Impact factor: 5.265